Genentech, Tercica, Insmed Settle Patent Suit

Law360, New York (March 7, 2007, 12:00 AM EST) -- Biotechnology companies Genentech Inc. and Tercica Inc. settled their lawsuit against rival start-up Insmed Inc. on Wednesday, ending a three-year-long patent scrimmage over Iplex, a drug used to treat hormone deficiencies in children.

In December, a California jury awarded $7.5 million plus royalties to Genentech and Tercica, after a “clean sweep” verdict found that Insmed had infringed on their patents for Iplex.

After an 11-day trial and seven days of deliberations, the jury ordered defendant Insmed to pay the Silicon Valley partners 15% royalties on up...
To view the full article, register now.